A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Verses in Combination with Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
MD Anderson Study Status
Acalabrutinib, Bendamustine, Rituximab, Placebo
This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Lymphoma, Mantle Cell
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.